2 completed, 2 terminated, 1 unknown. 5 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 2, Terminated 2, Unknown 1 |
| Phase 2 | 2 | Completed 1, Unknown 1 |
Follow Cantex Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma Azeliragon 5 mg, Azeliragon 10 mg, Azeliragon 20 mg - Glioblastoma | Phase 1 / Phase 2 | Completed | Cantex Pharmaceuticals | 33 | 2023-09-05 | 2026-10-19 |
| Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer Azeliragon - Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Unknown | Cantex Pharmaceuticals | 30 | 2023-06-01 | 2024-06-14 |
| Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma Disulfiram, Copper Gluconate - Multiple Myeloma | Phase 1 | Terminated | University of Utah | 2 | 2021-05-21 | 2023-03-13 |
| A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer Copper, Disulfiram, Copper gluconate - Prostate Cancer | Phase 1 | Terminated | Daniel George, MD | 9 | 2017-07-11 | 2021-09-16 |
| CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia CX-01, Azacitidine, Bone marrow biopsy - Myelodysplastic Syndromes, Acute Myeloid Leukemia | Phase 1 | Completed | Washington University School of Medicine | 20 | 2017-04-07 | 2019-12-05 |
Glioblastoma (1) · Leukemia, Myeloid, Acute (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1)
Disulfiram (2) · Gluconates (2) · azeliragon (2) · Azacitidine (1) · Copper (1) · N-desulfated,2-O,3-O-desulfated heparin (1)
United States (4) · Spain (1)
Andrew Hendifar, MD (1) · Daniel George, MD (1) · Douglas Sborov, MD (1) · Peter Westervelt, M.D., Ph.D. (1)